Symptomdx.

Get Started

Bulimia Nervosa (Medical Complications)MANAGEMENT

PSYCHIATRIC PRESENTATIONS · 12 SECTIONS

⚲

777 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Acute anxiety Acute psychosis Agitation-behavioral emergency Anorexia Nervosa (Medical Complications)Bipolar disorder Bipolar Disorder (Depressive Episode)Bipolar Disorder (Manic Episode)Bulimia Nervosa (Medical Complications)Catatonia Conversion disorder Dementia and behavioral crisis Factitious Disorder Failure to Cope (Social)Failure to Thrive Generalized Anxiety Disorder Homicidal Ideation Major Depressive Disorder Major depressive episode Malingering Neuroleptic malignant syndrome Panic Attack Post-Traumatic Stress Disorder (Acute)Schizophrenia Exacerbation Suicidal Ideation Suicidal ideation and attempt Suicide Attempt

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp68

Immediate priorities

›Cardiac instability threats

›Hypokalemia-driven arrhythmia

›K+ <3.0 mmol/l triggers continuous cardiac monitoring

›QTc >500 ms requires urgent electrolyte correction and medication review

›Ventricular arrhythmia risk greatest when K+ <2.5 mmol/l

›Hemodynamic compromise

›HR <50 or >120 bpm

›SBP <90 mmHg or orthostatic drop >20 mmHg

›Temperature <35.6 C

›If cardiac arrhythmia with hemodynamic instability, initiate ACLS protocol

›IV access x2 large bore

›12-lead ECG immediately

›Electrolyte emergency

›Profound hypokalemia K+ <2.5 mmol/l with symptoms

›Muscle weakness or paralysis

›Respiratory muscle compromise

›IV KCl 10-20 mEq/hr via central line with continuous monitoring

›Seizure activity

›Severe hypokalemia or hyponatremia trigger

›Hypoglycemia from caloric restriction

›Benzodiazepine for acute seizure control

›Volume depletion with AKI

›BUN:Cr ratio >20:1

›IV normal saline required before potassium will correct

›Life-threatening GI complications

›Boerhaave syndrome (esophageal rupture)

›Severe chest or epigastric pain after forceful vomiting

02History/hx82

Purging behaviors

›Purging method characterization

›Self-induced vomiting

›Frequency per day and per week

›Duration of behavior in months or years

›Digital vs spontaneous vs medication-induced

›Laxative misuse

›Type, dose, and daily frequency

›Stimulant laxatives vs osmotic agents

›Diuretic misuse

›Type and frequency

›Prescribed vs unprescribed

›Other compensatory behaviors

›Excessive exercise

›Ipecac use (irreversible myopathy risk; inquire specifically)

›Diet pill or herbal supplement use

›Insulin restriction in type 1 diabetes (diabulimia)

Binge episodes

›Binge characteristics

›Frequency per week

›DSM-5-TR severity: mild 1-3/week, moderate 4-7/week, severe 8-13/week, extreme 14+/week

›Average binge approximately 2,400 kcal up to 4,000 kcal

›Sense of loss of control during episode

›Triggers

›Stress, negative emotion, body image distress

›Prolonged restriction or fasting between episodes

›Social situations involving food

03Physical Exam/exam64

Vital signs

›Vital sign abnormalities

›Orthostatic hypotension

›BP drop >20/10 mmHg supine to standing

›Significant marker of volume depletion

›Resting or orthostatic tachycardia

›Pulse increase >20 bpm on standing

›Bradycardia

›HR <50 bpm if concurrent caloric restriction

›Hypothermia

›Temperature <36 C from metabolic suppression

›Weight and BMI

›Often normal or overweight; normal weight does not exclude diagnosis

HEENT

›Head and neck findings

›Parotid and salivary gland enlargement (sialadenosis)

›Bilateral, painless parotid enlargement

›Highly specific for recurrent vomiting

›From repetitive salivary gland stimulation

›Dental enamel erosion

›Lingual surfaces of upper anterior teeth preferentially affected

›Moth-eaten or translucent appearance

›Irreversible; dental referral required

›Palatal erythema or scratches

›From finger or object contact during induced vomiting

›Angular stomatitis

›Nutritional deficiency marker

›Oral mucosal changes

04Differential Diagnosis/ddx56

Conditions mimicking purging physiology

›Electrolyte pattern mimics

›Bartter syndrome

›Unexplained hypokalemic metabolic alkalosis without purging

›Urine chloride >25 mEq/L distinguishes from vomiting-induced alkalosis

›ICD-10: Q61.1

›Gitelman syndrome

›Hypokalemia, hypomagnesemia, metabolic alkalosis

›Urine chloride elevated; genetic testing confirms

›ICD-10: E87.6

›Diuretic abuse without eating disorder

›Urine diuretic metabolites positive

›No binge-purge behavioral pattern

›Primary hyperaldosteronism

›Hypokalemia with hypertension and metabolic alkalosis

›Aldosterone-to-renin ratio elevated

GI and structural mimics

›Gastrointestinal conditions

›Cyclic vomiting syndrome

›Episodic, stereotyped vomiting without binge eating

›Associated migraine history

›ICD-10: G43.A0

›Gastroparesis

›Chronic nausea and vomiting after meals

›Gastric emptying study confirms

›ICD-10: K31.84

›Crohn disease or celiac disease

›Weight loss and GI symptoms without behavioral pattern

05Laboratory Tests/lt64

Electrolytes and acid-base

›Basic metabolic panel

›Potassium (most critical)

›Hypokalemia hallmark of vomiting: K+ typically 2.5-3.5 mmol/l

›Severe: K+ <2.5 mmol/l; profound: K+ <2.0 mmol/l

›Drives arrhythmia risk; cardiac monitoring at K+ <3.0

›Laxative abuse pattern: hyperchloremic non-anion gap metabolic acidosis with K+ loss

›Chloride

›Hypochloremia from vomiting (loss of HCl)

›Helps establish vomiting vs laxative as predominant purging method

›Bicarbonate

›Elevated (>30 mmol/l) with vomiting: metabolic alkalosis

›Decreased with laxative abuse: hyperchloremic metabolic acidosis

›Sodium

›Hyponatremia from water loading or SIADH

›Correct slowly if chronic hyponatremia to avoid osmotic demyelination

Renal and hematologic

›Renal function

›BUN and creatinine

›Elevated BUN:Cr ratio >20:1 suggests dehydration

›AKI from chronic volume depletion and electrolyte-driven tubular injury

›Urine electrolytes

›Urine chloride <25 mEq/L in vomiting-induced alkalosis

›Urine chloride >25 mEq/L in Bartter/Gitelman or diuretic use

›Urine specific gravity: high with dehydration, low with water loading

›Complete blood count

›Leukopenia

›From malnutrition-associated bone marrow suppression

06Diagnostic Tests/dt74

Scoring Systems

›DSM-5-TR severity classification

›Severity based on compensatory behavior frequency per week

›Mild: 1-3 episodes per week

›Moderate: 4-7 episodes per week

›Severe: 8-13 episodes per week

›Extreme: 14 or more episodes per week

›Diagnostic criteria require binge eating and compensatory behaviors

›Minimum once weekly for 3 months

›Not attributable to anorexia nervosa

›ICD-10: F50.2

›SCOFF Questionnaire

›Validated 5-question screening tool

›Sick (do you make yourself sick because you feel full?)

›Control (do you worry you have lost control over how much you eat?)

›One stone (have you lost more than one stone [6.4 kg] recently?)

›Fat (do you believe yourself to be fat when others say too thin?)

›Food (does food dominate your life?)

›Score ≥2 positive: high sensitivity for eating disorder

›USPSTF Grade B recommendation for screening in adolescents and adults

›Eating Disorder Examination Questionnaire (EDE-Q)

›Self-report tool for eating disorder psychopathology

›Assesses restraint, eating concern, shape concern, weight concern

›Useful for severity tracking over time

›Not validated as an emergency screening tool

MRI

›Brain MRI indications

›Structural CNS lesion suspected as cause of vomiting

07Disposition/dispo48

Admission criteria

›Medical indications for inpatient admission

›Electrolyte instability

›K+ <3.0 mmol/l requiring IV repletion

›Hyponatremia <130 mmol/l

›Hypophosphatemia <0.6 mmol/l

›Cardiac instability

›QTc >500 ms

›HR <50 or sustained tachycardia >120

›Arrhythmia on monitoring

›Hemodynamic instability

›SBP <90 mmHg or orthostatic drop >20 mmHg

›Temperature <35.6 C

›Dehydration requiring IV fluid resuscitation

›Acute medical complications

›Syncope or seizure

›Cardiac failure or arrhythmia

›Pancreatitis or GI perforation

›Uncontrollable binge-purge cycles despite outpatient management

›Psychiatric emergency

›Suicidal ideation with plan or intent

›Severe depression precluding safe outpatient management

ICU and step-down criteria

›ICU-level care triggers

›Cardiac arrhythmia requiring continuous intervention

›Boerhaave syndrome post-operative

›Refractory hypokalemia with respiratory muscle weakness

›Hemodynamic shock

08Treatment/t92

Acute electrolyte repletion

›Potassium repletion protocol

›Mild-moderate hypokalemia K+ 3.0-3.5 mmol/l

›Oral KCl 40-80 mEq/day in split doses

›K+ rich foods as adjunct (bananas, potatoes, citrus)

›Recheck in 2-4 hours

›Moderate hypokalemia K+ 2.5-3.0 mmol/l

›IV normal saline first to correct volume depletion

›Volume depletion activates renin-angiotensin system preventing K+ correction

›IV KCl 10 mEq/hr via peripheral line after volume repleted

›Recheck every 2 hours

›Severe hypokalemia K+ <2.5 mmol/l or symptomatic

›IV KCl 10-20 mEq/hr via central line

›Continuous cardiac monitoring mandatory

›Maximum 40 mEq/hr only in life-threatening situations

›Recheck every 1-2 hours

›Magnesium repletion

›Hypomagnesemia Mg2+ <0.75 mmol/l

›IV magnesium sulfate 1-2 g over 1 hour

›Repeat as needed; target >0.75 mmol/l

›Oral magnesium glycinate 200-400 mg/day for mild depletion

›Refractory hypokalemia will not correct until Mg2+ repleted

›Phosphorus repletion

›Mild hypophosphatemia 0.6-0.8 mmol/l

›Oral phosphate sodium or potassium phosphate 250-500 mg TID

›Severe hypophosphatemia <0.5 mmol/l

›IV sodium or potassium phosphate 0.08-0.16 mmol/kg over 6 hours

›Cardiac monitoring during IV repletion

›Recheck every 4-6 hours

Volume resuscitation

›IV fluid strategy

›Normal saline (0.9% NaCl) as first-line

›1-2 L bolus for significant dehydration

›Replaces volume depletion and turns off renin-angiotensin system

›Essential prerequisite to effective K+ correction

›Avoid hypotonic fluids initially

›Risk of hyponatremia worsening

›Transition to oral hydration when hemodynamically stable

›Isotonic oral solutions preferred

›Monitor urine output target 0.5-1 mL/kg/hr

Pharmacotherapy

›FDA-approved medication

›Fluoxetine (SSRI)

›Only FDA-approved medication for bulimia nervosa

›Target dose 60 mg/day orally

›Superior efficacy at 60 mg vs 20 mg/day

›Titrate up over 1-2 weeks to minimize GI side effects

›Class I recommendation based on multiple RCTs

›Reduces binge-purge frequency by approximately 50%

›Initiate when electrolytes stabilized

›Contraindicated medications

›Bupropion

›Contraindicated in bulimia nervosa; seizure risk significantly increased

›Risk appears related to purging-induced electrolyte abnormalities lowering seizure threshold

›QTc-prolonging agents requiring caution

›TCAs (avoid if K+ abnormal)

›Ondansetron (use with caution; monitor QTc)

›Haloperidol and certain other antipsychotics

›Antiemetics

›Metoclopramide 10 mg IV/oral for nausea

›Avoid prolonged use (tardive dyskinesia risk)

›Ondansetron 4 mg IV with caution

›Monitor QTc if hypokalemia present

›Thiamine supplementation

›Thiamine 100 mg IV or oral before glucose or refeeding

›Prevents Wernicke encephalopathy in malnourished patients

›B-complex vitamins as adjunct

Nutritional rehabilitation

›Structured refeeding protocol

›Acute setting

›Regular structured meals; eliminate forbidden food lists

›Dietitian involvement for meal planning

›Avoid prolonged fasting between meals

›Refeeding syndrome prevention

›Start at 50% estimated caloric need if significantly malnourished

›Advance by 200 kcal/day every 1-2 days

›Monitor K+, PO4, Mg2+ daily for first week

›Thiamine before refeeding initiation

›Laxative and diuretic withdrawal

›Abrupt cessation causes rebound peripheral edema

›Counsel that edema is expected and self-limited (resolves in 2-4 weeks)

›Does not represent true weight gain

Psychotherapy

›Evidence-based behavioral interventions

›Cognitive behavioral therapy (CBT)

›Gold-standard for bulimia nervosa in adults

›Targets cognitive distortions about body image and food

›Typically 20 sessions over 20 weeks

›Class I recommendation; strongest evidence base

›Family-based therapy (FBT)

›First-line for adolescents with bulimia nervosa

›Parents supported to take temporary control of refeeding

›Interpersonal psychotherapy (IPT)

›Second-line when CBT unavailable or refused

›Targets interpersonal triggers for binge-purge behavior

›Dialectical behavioral therapy (DBT)

›For patients with co-occurring borderline personality disorder or severe emotion dysregulation

09Special Populations/sp72

Pregnancy

›Pregnancy-specific risks

›Maternal risks

›Preterm birth and low birth weight from maternal malnutrition

›Hyperemesis gravidarum overlap; distinguish from purging behavior

›Electrolyte derangements more dangerous with fetal cardiac impact

›Increased miscarriage risk

›Gestational hypertension risk

›Fetal risks

›Intrauterine growth restriction from malnutrition

›Neural tube defects from folate and vitamin deficiency

›Fetal arrhythmia if maternal hypokalemia severe

›Management modifications

›Medication safety

›Fluoxetine: Use with caution; generally considered lower risk SSRI in pregnancy

›Avoid TCAs; increased congenital risk

›Folate supplementation 5 mg/day (higher than standard)

›Electrolyte repletion unchanged in principle

›K+ correction follows same protocol; more urgent given fetal impact

›Multidisciplinary team

›Maternal-fetal medicine consultation

›Psychiatry with perinatal expertise

›Registered dietitian with obstetric experience

›Monitoring

›More frequent electrolyte checks (every 1-2 weeks if outpatient)

›Fetal growth ultrasounds every 4 weeks from 28 weeks if nutritional compromise

Geriatric

›Age-related considerations

›Epidemiology

›Less commonly recognized in older adults; often undiagnosed

›Can be chronic illness from younger onset or new onset in 60s-70s

›Late-onset bulimia often triggered by major life stressor

›Physiologic vulnerabilities

›Reduced renal reserve worsens electrolyte derangements

›Reduced cardiac reserve increases arrhythmia risk at milder K+ deficits

›Sarcopenia compounds muscle weakness from hypokalemia

›Bone fragility from osteoporosis increased in those with chronic illness

›Medication considerations

›Polypharmacy increases QTc prolongation risk

›Review all medications for QTc effects before adding fluoxetine

›Start fluoxetine at lower dose (20 mg) and titrate slowly

›Renal dosing adjustment for fluoxetine if eGFR <30 mL/min/1.73m2

›Electrolyte repletion caution

›Slower potassium infusion rates to avoid volume overload

›Monitor cardiac function more closely during repletion

›Cognitive assessment

›Cognitive impairment may affect treatment engagement

›Caregiver involvement in management planning

Pediatrics

›Pediatric-specific features

›Epidemiology

›Peak onset in adolescence; mean age 18 years

›Less common under age 12

›Males represent up to 25% of pediatric eating disorder patients

›Growth and development

›Linear growth impairment from caloric restriction

›Delayed or disrupted pubertal development

›Bone mineral density accrual impaired; life-long fracture risk

›DEXA scan indicated if amenorrhea >6 months

›AAP and SAHM admission criteria

›HR <50 bpm daytime or <45 bpm nighttime

›BP <90/45 mmHg

›Orthostatic change >20 bpm or >20 mmHg

›Temperature <35.6 C

›K+ <3.0 mmol/l

›QTc >450 ms in pediatrics (lower threshold than adults)

›Medication adjustments

›Fluoxetine FDA-approved for ages 8+ for depression; off-label for bulimia in adolescents

›Start 10-20 mg/day; titrate to 60 mg/day with monitoring

›TCAs contraindicated in pediatric eating disorders

›Family-based therapy

›Strongest evidence for adolescents; preferred over individual CBT

›Involves parents directly in behavioral change

›Mandatory reporting

›Medical neglect considerations if guardians not engaged in treatment

10Background/b95

Epidemiology

›Prevalence and demographics

›Lifetime prevalence approximately 1-3% in women; 0.1-0.5% in men

›Males significantly underdiagnosed due to stigma and atypical presentation

›Disproportionate rates in athletes, dancers, and performers

›Age distribution

›Onset typically in adolescence and young adulthood (ages 15-25)

›Mean age of onset approximately 18 years

›Late-onset cases (40s-60s) increasingly recognized

›Mortality and morbidity

›Crude mortality rate approximately 4 per 1,000 person-years

›Standardized mortality ratio 2-3x general population

›Suicide is a leading cause of death in all eating disorders

›Women with bulimia nervosa have >4x risk of CVD and premature death (JAMA Psychiatry, 2020)

›Heritability and genetics

›Heritability estimated at 50-83%

›Multiple susceptibility genes identified (serotonin, dopamine pathways)

›Shared genetic architecture with mood disorders and substance use

Pathophysiology

›Purging-driven electrolyte derangements

›Vomiting mechanism

›Loss of hydrochloric acid from gastric secretion

›Results in hypochloremic metabolic alkalosis

›Compensatory aldosterone activation worsens K+ loss

›Volume depletion activates renin-angiotensin system perpetuating alkalosis

›Laxative abuse mechanism

›Loss of bicarbonate-rich colonic fluid

›Results in hyperchloremic metabolic acidosis

›Potassium lost in stool; osmotic agents less damaging than stimulant laxatives

›Diuretic abuse mechanism

›Loop or thiazide diuretics cause K+ and Mg2+ loss

›Volume depletion and secondary hyperaldosteronism

›Cardiac pathophysiology

›Hypokalemia cardiac effects

›Hyperpolarizes myocardial cell membrane

›Prolongs action potential duration and QTc

›Increases automaticity and re-entry arrhythmia risk

›U waves on ECG from altered repolarization

›Ipecac cardiomyopathy

›Emetine directly toxic to cardiac and skeletal myocytes

›Irreversible mitochondrial damage with chronic use

›Reduces ejection fraction; may cause CHF

›Dental and GI pathophysiology

›Dental enamel erosion

›Gastric acid (pH <2.0) demineralizes enamel

›Lingual surfaces of upper anterior teeth preferentially affected

›Perimolysis (acid erosion from vomiting) irreversible

›Sialadenosis

›Autonomic stimulation from repeated vomiting enlarges parotid glands

›Non-inflammatory; bilateral painless swelling

›GI mucosal damage

›Esophagitis from repetitive acid exposure

›Barrett esophagus risk from chronic GERD

›Mallory-Weiss tears at gastroesophageal junction

›Boerhaave syndrome: full-thickness rupture from extreme intragastric pressure

›Neurobiology

›Serotonin system dysregulation

›5-HT1A and 5-HT2A receptor alterations

›Impaired satiety signaling

›Basis for fluoxetine efficacy

›Dopamine and reward dysregulation

›Binge eating activates mesolimbic reward pathways similar to addiction

›Explains compulsive quality of binge episodes

›HPA axis dysregulation

›Elevated cortisol with active purging

›Contributes to bone loss and immune suppression

Therapeutic Considerations

›Evidence base for pharmacotherapy

›Fluoxetine 60 mg/day

›Only FDA-approved pharmacotherapy for bulimia nervosa

›Multiple RCTs demonstrate reduction in binge-purge frequency

›Number needed to treat approximately 4-5 for remission

›APA Practice Guideline recommends as first-line pharmacotherapy (2023)

›Inferior to CBT alone; combined CBT + fluoxetine superior to either alone

›Other antidepressants

›SSRIs (sertraline, citalopram) used off-label when fluoxetine not tolerated

›Avoid bupropion in all patients with bulimia nervosa

›MAOIs: efficacy evidence exists but rarely used due to safety profile

›Evidence base for psychotherapy

›CBT-BN

›Strongest evidence; remission rates 30-50% in RCTs

›Targets cognitive distortions and behavioral patterns

›ACEP Level A equivalent for psychosocial interventions

›Guided self-help CBT

›Effective for mild-moderate severity when therapist access limited

›NICE guideline recommended first step in care pathway

›Long-term outcome

›Recovery rates

›50-70% achieve full recovery with treatment over 10 years

›Higher recovery rates than anorexia nervosa

›Relapse common; ongoing monitoring required

›Untreated course

›Chronic relapsing illness; spontaneous remission possible but uncommon

›Transition to anorexia nervosa in 10-15% over time

›Cumulative medical complications worsen with duration of illness

›Hospitalization indications per APA 2023 guidelines

›Medical instability as primary driver

›Outpatient or residential treatment preferred when medically stable

11Patient Discharge Instructions/pdi37

copy discharge instructions

›Discharge instructions for bulimia nervosa

›Your diagnosis

›You were treated for bulimia nervosa with medical complications

›Your electrolytes (blood salts) were low and have been corrected

›It is very important to follow up with your doctors to keep these levels normal

›Medications

›Take all prescribed medications as directed

›Do not stop or change your medications without talking to your doctor

›If prescribed fluoxetine (Prozac), it may take several weeks to notice improvement

›Eating and drinking

›Try to eat regular, balanced meals 3 times a day plus snacks

›Avoid skipping meals as this can trigger binge episodes

›Drink adequate fluids to stay hydrated

›Work with a registered dietitian experienced in eating disorders

›Important side effects to know about

›If you stop laxatives or diuretics, you may notice temporary swelling in your legs

›This swelling is normal and will go away on its own within 2-4 weeks

›This swelling does not mean you are gaining weight permanently

›Dental care

›See a dentist as soon as possible for assessment of your teeth

›After vomiting, rinse with water or a fluoride rinse but do not brush immediately

›Brushing immediately after vomiting worsens enamel damage

›Mental health support

›Attend your psychiatry or therapy appointments

›Cognitive behavioral therapy (CBT) is the most effective treatment for bulimia nervosa

›Recovery is achievable; most people with bulimia nervosa do recover with treatment

›Appointments to keep

12References/r25

Guidelines and key sources

›Primary guidelines

›American Psychiatric Association Practice Guideline for Eating Disorders (2023)

›Crone C, Fochtmann LJ, Attia E, et al. American Journal of Psychiatry. 2023

›Comprehensive guideline for pharmacotherapy and psychotherapy

›AAP Clinical Report: Identification and Management of Eating Disorders in Children and Adolescents

›Hornberger LL, Lane MA. Pediatrics. 2021

›Admission criteria and adolescent-specific management

›USPSTF Recommendation: Screening for Eating Disorders in Adolescents and Adults (2022)

›Davidson KW, Barry MJ, et al. JAMA. 2022

›Grade B recommendation for screening

Landmark studies and reviews

›Key evidence

›Attia E, Walsh BT. Eating Disorders: A Review. JAMA. 2025

›Comprehensive review of diagnosis and management across eating disorders

›Treasure J, Duarte TA, Schmidt U. Eating Disorders. Lancet. 2020

›Epidemiology, pathophysiology, and treatment evidence

›Tith RM, Paradis G, Potter BJ, et al. Association of Bulimia Nervosa With Long-term Risk of Cardiovascular Disease and Mortality Among Women. JAMA Psychiatry. 2020

›Women with bulimia nervosa have greater than 4x risk of CVD and premature death

›Krantz MJ, Blalock DV, Tanganyika K, et al. Is QTc-Interval Prolongation an Inherent Feature of Eating Disorders? American Journal of Medicine. 2020

›QTc prolongation driven by hypokalemia and QTc-prolonging medications not intrinsic to eating disorder; cohort of 906 patients

›Hundemer GL, Clarke A, Akbari A, et al. Analysis of Electrolyte Abnormalities in Adolescents and Adults and Subsequent Diagnosis of an Eating Disorder. JAMA Network Open. 2022

›Unexplained hypokalemia and hypochloremia predictors of subsequent eating disorder diagnosis

›Mehler PS. Bulimia Nervosa. NEJM. 2003

›Classic clinical review; medical complications and management

›Klein DA, Sylvester JE, Schvey NA. Eating Disorders in Primary Care: Diagnosis and Management. American Family Physician. 2021

›Primary care approach including SCOFF questionnaire and management algorithms

Learn More: Bulimia Nervosa (Medical Complications)→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.